What Happened

Vaxart announced topline 12-month safety data from its Phase 2b trial comparing an oral COVID-19 vaccine to an mRNA comparator. The 400-participant sentinel cohort showed no vaccine-related serious adverse events, with comparable COVID case counts between arms.

Who Is Affected

Vaxart's clinical team and investors are directly impacted as the company progresses toward its 2027 full trial readout. Pharmaceutical partners evaluating oral vaccine platforms should monitor this $344.8M-funded program.

Market Impact

• Validates oral vaccine approach with clean safety profile
• Locks in $344.8M Project NextGen funding
• Sets stage for 2027 commercial decisions with 5,000-participant data

What to Watch

Monitor the main cohort's KP.2 strain efficacy data in 2027, which will determine commercial viability. Vaxart's $300M shelf offering could trigger dilution if development costs escalate.